Synvista Therapeutics, Inc. (SYNI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Synvista Therapeutics, Inc. (SYNI) with AI Score 46/100 (Weak). Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Synvista Therapeutics, Inc. (SYNI) Healthcare & Pipeline Overview
Synvista Therapeutics, Inc. is a biopharmaceutical company specializing in treatments for diabetic patients at risk of cardiovascular disease. Their pipeline features ALT-2074, a glutathione peroxidase mimetic, and Alagebrium chloride, an Advanced Glycation End-product Crosslink Breaker, both currently in Phase II clinical trials, positioning them in the competitive pharmaceuticals market.
Investment Thesis
Synvista Therapeutics, Inc. presents a high-risk, high-reward investment profile due to its focus on developing treatments for diabetic patients at risk of cardiovascular disease. The company's pipeline, featuring ALT-2074 and Alagebrium chloride in Phase II trials, represents potential value drivers if clinical trials are successful. However, the company's small market capitalization and OTC listing introduce significant liquidity and regulatory risks. Successful completion of Phase II trials and subsequent partnerships or acquisitions could drive significant returns. The company's beta of -5.15 suggests an inverse correlation with the market, which may offer diversification benefits in certain market conditions.
Based on FMP financials and quantitative analysis
Key Highlights
- Synvista Therapeutics focuses on developing diagnostic tests and drugs for diabetic patients at high risk for cardiovascular disease.
- The company's lead product candidates, ALT-2074 and Alagebrium chloride, are both in Phase II clinical trials.
- ALT-2074 is a glutathione peroxidase mimetic for the treatment of diabetic patients with Hp2-2.
- Alagebrium chloride is an Advanced Glycation End-product Crosslink Breaker for the treatment of diastolic heart failure and diabetic nephropathy.
- Synvista Therapeutics trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Competitors & Peers
Strengths
- Focus on a specific niche within diabetes care (cardiovascular complications).
- Proprietary drug candidates in Phase II clinical trials.
- Potential for high returns if clinical trials are successful.
Weaknesses
- Small market capitalization and limited financial resources.
- Reliance on a small number of drug candidates.
- OTC listing indicates higher risk and lower liquidity.
Catalysts
- Upcoming: Release of Phase II clinical trial results for ALT-2074.
- Upcoming: Announcement of potential partnerships with larger pharmaceutical companies.
- Upcoming: Progress on the development of a diagnostic test for cardiovascular risk in diabetic patients.
Risks
- Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.
- Ongoing: Competition from larger pharmaceutical companies with more resources.
- Potential: Regulatory hurdles and delays in FDA approval.
- Ongoing: Limited financial resources and reliance on external funding.
- Ongoing: Risks associated with trading on the OTC market, including low liquidity and price volatility.
Growth Opportunities
- Successful completion of Phase II clinical trials for ALT-2074: Positive results from the Phase II trials could lead to increased investor confidence and potential partnerships with larger pharmaceutical companies. The market for treatments targeting diabetic patients with the Hp2-2 genotype is significant, offering a substantial revenue opportunity if the drug proves effective. The timeline for Phase III trials and potential FDA approval could extend several years, but successful Phase II data would be a major catalyst.
- Advancement of Alagebrium chloride through clinical trials: Alagebrium chloride targets diastolic heart failure and diabetic nephropathy, both significant complications of diabetes. Positive clinical trial results could open up a large market opportunity. The development timeline is lengthy, but successful trials would significantly increase the company's value. The market for heart failure and diabetic nephropathy treatments is substantial and growing.
- Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients: A successful diagnostic test could provide a recurring revenue stream and differentiate Synvista from competitors. The market for diagnostic tests in diabetes is expanding, driven by the need for early detection and prevention of complications. The timeline for development and commercialization depends on regulatory approval and market adoption.
- Strategic partnerships with larger pharmaceutical companies: Collaborations with established pharmaceutical companies could provide Synvista with funding, expertise, and access to larger markets. Partnerships could accelerate the development and commercialization of Synvista's products. The pharmaceutical industry is characterized by collaborations between smaller biotech firms and larger companies, offering potential opportunities for Synvista.
- Expansion into new therapeutic areas within diabetes: Synvista could leverage its expertise in diabetes to develop treatments for other complications, such as retinopathy and neuropathy. Expanding the product pipeline would diversify the company's revenue streams and reduce its reliance on a single product. The market for diabetes treatments is broad and offers numerous opportunities for innovation.
Opportunities
- Successful completion of Phase II trials could lead to partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas within diabetes.
- Development and commercialization of a diagnostic test for cardiovascular risk in diabetic patients.
Threats
- Failure of clinical trials.
- Competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles and delays in FDA approval.
Competitive Advantages
- Proprietary drug candidates with patent protection.
- Specialized focus on cardiovascular complications of diabetes.
- Clinical trial data demonstrating safety and efficacy.
About SYNI
Synvista Therapeutics, Inc., formerly known as Alteon, Inc., was founded in 1986 and is headquartered in Parsippany, New Jersey. The company operates as a product-based biopharmaceutical entity, focusing on the development of diagnostic tests and drugs aimed at identifying and treating diabetic patients who are at high risk of developing cardiovascular disease. Synvista's product pipeline includes ALT-2074, a glutathione peroxidase mimetic currently in Phase II clinical trials for treating diabetic patients with the Hp2-2 genotype. Additionally, they are developing Alagebrium chloride, also in Phase II clinical trials, targeting diastolic heart failure and diabetic nephropathy. The company is also working on a diagnostic test designed to identify and treat diabetic patients at risk of cardiovascular disease. Synvista's strategic focus on diabetes-related cardiovascular complications positions it within a niche segment of the pharmaceutical industry, addressing a significant unmet medical need.
What They Do
- Develop diagnostic tests for diabetic patients at high risk for cardiovascular disease.
- Develop drugs to treat diabetic patients at high risk for cardiovascular disease.
- Focus on glutathione peroxidase mimetics for treating diabetic patients with Hp2-2.
- Develop Advanced Glycation End-product Crosslink Breakers for treating diastolic heart failure and diabetic nephropathy.
- Conduct Phase II clinical trials for ALT-2074.
- Conduct Phase II clinical trials for Alagebrium chloride.
Business Model
- Develops and patents novel therapeutic compounds.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
Industry Context
Synvista Therapeutics operates within the medical pharmaceutical industry, a sector characterized by intense research and development, stringent regulatory oversight, and high capital requirements. The market for diabetes-related treatments is substantial, driven by the increasing prevalence of diabetes globally. Competition includes major pharmaceutical companies and smaller biotech firms focusing on innovative therapies. Synvista's focus on cardiovascular complications of diabetes positions it within a specialized niche, potentially offering a competitive advantage if its clinical trials are successful. The industry is also influenced by trends in personalized medicine and diagnostic testing, aligning with Synvista's development of a diagnostic test for cardiovascular risk in diabetic patients.
Key Customers
- Diabetic patients at high risk for cardiovascular disease.
- Hospitals and clinics specializing in diabetes care.
- Pharmaceutical companies seeking to expand their diabetes product portfolios.
Financials
Chart & Info
Synvista Therapeutics, Inc. (SYNI) stock price: Price data unavailable
Latest News
No recent news available for SYNI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SYNI.
Price Targets
Wall Street price target analysis for SYNI.
MoonshotScore
What does this score mean?
The MoonshotScore rates SYNI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
SYNI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Synvista Therapeutics, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited or no financial disclosure, making it difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a significantly higher risk compared to companies listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of price manipulation.
- Potential for delisting or suspension of trading.
- Lack of regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Research the company's industry and market trends.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Company has been in operation since 1986.
- Focus on developing treatments for a specific medical need (diabetes-related cardiovascular complications).
- Drug candidates are in Phase II clinical trials.
What Investors Ask About Synvista Therapeutics, Inc. (SYNI)
What does Synvista Therapeutics, Inc. do?
Synvista Therapeutics, Inc. is a biopharmaceutical company focused on developing diagnostic tests and drugs for diabetic patients who are at high risk of developing cardiovascular disease. Their primary focus is on developing treatments for diabetic patients with the Hp2-2 genotype and for diastolic heart failure and diabetic nephropathy. The company's pipeline includes ALT-2074, a glutathione peroxidase mimetic, and Alagebrium chloride, an Advanced Glycation End-product Crosslink Breaker, both currently in Phase II clinical trials. Synvista also aims to develop a diagnostic test to identify diabetic patients at risk of cardiovascular disease, positioning them as a player in the personalized medicine approach to diabetes care.
What do analysts say about SYNI stock?
As of 2026-03-16, there is no available analyst coverage for Synvista Therapeutics, Inc. due to its OTC listing and small market capitalization. The company's valuation is highly dependent on the success of its clinical trials and its ability to secure partnerships or funding. Investors should conduct their own due diligence and carefully consider the risks associated with investing in a small, OTC-listed biopharmaceutical company. The lack of analyst coverage underscores the importance of independent research and a thorough understanding of the company's prospects and challenges.
What are the main risks for SYNI?
The main risks for Synvista Therapeutics, Inc. include the inherent risks associated with pharmaceutical development, such as the failure of clinical trials, regulatory hurdles, and competition from larger companies with more resources. The company's reliance on a small number of drug candidates increases its vulnerability to setbacks in clinical development. Additionally, its OTC listing exposes investors to risks associated with low liquidity, price volatility, and limited financial disclosure. Securing adequate funding to support ongoing clinical trials and operations is also a significant risk factor. Investors should carefully assess these risks before investing in Synvista Therapeutics, Inc.
What are the key factors to evaluate for SYNI?
Synvista Therapeutics, Inc. (SYNI) currently holds an AI score of 46/100, indicating low score. Key strength: Focus on a specific niche within diabetes care (cardiovascular complications).. Primary risk to monitor: Potential: Failure of clinical trials for ALT-2074 or Alagebrium chloride.. This is not financial advice.
How frequently does SYNI data refresh on this page?
SYNI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven SYNI's recent stock price performance?
Recent price movement in Synvista Therapeutics, Inc. (SYNI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on a specific niche within diabetes care (cardiovascular complications).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider SYNI overvalued or undervalued right now?
Determining whether Synvista Therapeutics, Inc. (SYNI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying SYNI?
Before investing in Synvista Therapeutics, Inc. (SYNI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available sources and may be incomplete or outdated.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis pending for SYNI.